Clinical Use of Foscarnet (Phosphonoformate)

  • B. Öberg
  • S. Behrnetz
  • B. Eriksson
  • H. Jozwiak
  • A. Larsson
  • J. O. Lernestedt
  • V. Lindsö Aberg
Part of the Developments in Medical Virology book series (DIMV, volume 3)


Foscarnet is a selective inhibitor of several viral DNA polymerases. When used topically, foscarnet has a limited effect on recurrent mucocutaneous herpes, possibly due to the rapid course of virus replication. In immunocompromised patients with severe CMV infections, parenteral foscarnet has beneficial effects especially against CMV retinitis in AIDS patients. Preliminary data indicate that parenteral foscarnet decreases HIV replication in vivo. Following iv treatment with foscarnet for two weeks or longer and with median daily doses of 6 to 10 g in different subgroups of patients, transient renal impairment, decreases in haemoglobin concentration and calcium have been observed. Effects on the central nervous system, e.g. hallucinations and tremor, may be associated with high plasma foscarnet levels.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Graft Versus Host Disease Renal Transplant Patient Genital Herpes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Helgstrand, E., Eriksson, B., Johansson, N.-G., Lannerö, B., Larsson, A., Misiorny, A., Norén, J. O., Sjöberg, B., Stenberg, K., Stening, G., Stridh, S., Oberg, B., Alenius, S. and Philipson, L. Science 201: 819–821, 1978.PubMedCrossRefGoogle Scholar
  2. 2.
    Helgstrand, E., Alenius, S., Johansson, N.-G. and Öberg, B. In: Current Chemotherapy and Infectious Diseases 2 (Eds. J. D. Nelson and C. Grassi), American Society for Microbiology, Washington, D.C., 1980, pp. 1359–1361.Google Scholar
  3. 3.
    Öberg, B. Pharmac. Ther. 19: 387–415, 1983.CrossRefGoogle Scholar
  4. 4.
    Eriksson, B. and Öberg, B. In: Antiviral drugs and interferon: The molecular basis of their activity (Ed. Y. Becker), Martinus Nijhoff Publishing, Boston, 1984, pp. 127–142.Google Scholar
  5. 5.
    Oberg, B. In: Human Herpesvirus Infections: Pathogenesis, Diagnosis and Treatment (Eds. C. Lopez and B. Roizman), Raven Press, New York, 1986, pp. 141–151.Google Scholar
  6. 6.
    Öberg, B. Viral Chemotherapy. Ed. D. Shugar. Pergamon Press. In press, 1987Google Scholar
  7. 7.
    Wallin, J., Lernestedt, J.-O., Ogenstad, S. and Lycke, E. Scand. J. Inf. Dis. 17: 165–172, 1985.Google Scholar
  8. 8.
    Lassus, A., Vainio, E., Kalimo, K. and Eriksson, B. Manuscript.Google Scholar
  9. 9.
    Sacks, S. L., Portnoy, J., Lawee, D., Schlech III, W., Aoki, F. Y., Tyrrell, D. L., Poisson, M., Bright, C., Kaluski, J. and the Canadian Cooperative Study Group. J. Inf. Dis. In press, 1987.Google Scholar
  10. 10.
    Barton, S. E., Munday, P. E., Kinghorn, G. R., van der Meijden, W. I., Stolz, E., Notowicz, A., Rashid, S., Schuller, J. L., Essex-Cater, A. J., Kuijpers, M. H. M. and Chanas, A. C. Genitourin. Med. 62: 247–250, 1986.PubMedGoogle Scholar
  11. 11.
    Gundersen, T. et al. Manuscript.Google Scholar
  12. 12.
    Lönnqvist, B., Klintmalm, G., Öberg, B., Gahrton, G., Lernestedt, J.-O., Lundgren, G., Ringdén, I., Robert, K.-H. and Wahren, B. Third International Symposium on Infections in the Immunocompromised Host, Toronto, 1984, Abstract 150.Google Scholar
  13. 13.
    Ahlmén, J., Wijnween, A.-C, Brynger, H. and Lycke, E. Scand. J. Urol. Nephrol. Suppl. 92: 41–44, 1985.PubMedGoogle Scholar
  14. 14.
    Apperley, J. F., Marcus, R. E., Goldman, J. M., Wardle, D. G., Gravetti, P. J. and Chanas, A. Lancet I: 1151, 1985.Google Scholar
  15. 15.
    Gronowitz, J. S., Larsson, A., Källander, C. F. R., Claesson, K., Sjöberg, O., Lernestedt, J.-O., Frödin, L. and Tufveson, G. Ann. Clin. Res. 18: 71–75, 1985.Google Scholar
  16. 16.
    Klintmalm, G., Lönnqvist, B., Öberg, B., Gahrton, G., Lernestedt, J.-O., Lundgren, G., Ringdén, O., Robert, K.-H., Wahren, B. and Groth, C.-G. Scand. J. Inf. Dis. 17: 157–163, 1985.Google Scholar
  17. 17.
    Larsson, A., Frödin, L., Tufveson, G., Larsson, E., Källander, C. F. R. and Gronowitz, J. S. Scand. J. Urol. Nephrol. 20: 75–76, 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    Ringdén, O., Wilczek, H., Lönnqvist, B., Gahrton, G., Wahren, B. and Lernestedt, J.-O. Lancet I: 1503–1504, 1985.CrossRefGoogle Scholar
  19. 19.
    Ringdén, O., Lönnqvist, B., Paulin, T., Ahlmén, J., Bolme, P., Wahren, B., Wilczek, H. and Lernestedt, J.-O. Proc. 14th Int. Chemother. Meeting, Japan, 1985.Google Scholar
  20. 20.
    Wahren, B., Öberg, B., Wiklund, M., Lönnqvist, B., Ljungman, P., Ringdén, O., Lernestedt, J.O. and Gahrton, G. Excerpta Med. Int. Congress Series, Elsevier, 67–71, 1985.Google Scholar
  21. 21.
    Michon, C. P., Katlama, C., Le Hoang, P., Leport, C., Rowzioux, C., Matheron, S. et al. Int. Conf. on Acquired Immunodeficiency Syndrome (AIDS), Paris, 1986.Google Scholar
  22. 22.
    Modig, J., Hedstrand, U. and Tufveson, G. Manuscript.Google Scholar
  23. 23.
    Ringdén, O., Lönnqvist, B., Paulin, T., Ahlmén, J., Klintmalm, G., Wahren, B. and Lernestedt, J.-O. J. Antimicrob. Chemother. 17: 373–387, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Ringdén, O., Lönnqvist, B., Paulin, T., Ljungman, B. Wahren, B. and Lernestedt, J.-O. J. Cell Biochem. Suppl. D: 259, 1986.Google Scholar
  25. 25.
    Singer, D. R. J., Fallon, T. J., Schulenburg, W. W., Boyd, A. S., Cohen, J. and Williams, G. Proceedings EDTA Congress, 1986.Google Scholar
  26. 26.
    Weber, J. N., Thom, S., Unwin, R., Forster, S., Jeffries, D. J., Boylston, A. and Pinching, A. J. Gut. In press, 1987.Google Scholar
  27. 27.
    Åkesson, A., Lernestedt, J.-O., Ringdén, O., Lönnqvist, B. and Wahren, B. Bone marrow transplantation. In press, 1986.Google Scholar
  28. 28.
    Singer, D. R. J., Fallon, T. J., Schulenburg, W. E., Williams, G. and Cohen, J. Ann. Int. Med. 103: 962, 1985.Google Scholar
  29. 29.
    Le Huang, P., Dhermy, P., Robinet, M., Holgado, P. and Matheron, S. Second World Congress on Sexually Transmitted Diseases (STD), Paris, 1986. Abstract.Google Scholar
  30. 30.
    Robinet, M., Matheron, S., Katlama, C, Rozenbaum, W., Leport, C, Dhermy, P., Gaudric, A., Sterkers, M., Coulaud, J. P., Vilde, J. L., Gentilini, M. and Rousselie, F. Second World Congress on Sexually Transmitted Diseases (STD), Paris, 1986. Abstract.Google Scholar
  31. 31.
    Walmsley, S., Chew, E., Fanning, M., Coates, R. A., Salit, I. S., Shepherd, F. A., Rachlis, A. and Read, S. E. ICAAC, 1986. Abstract 568.Google Scholar
  32. 32.
    Farthing, C., Anderson, M. G., Ellis, M. E., Gazzard, B. G. and Chanas, A. C. J. Med. Virol. In press, 1987.Google Scholar
  33. 33.
    Gronowitz, J. S., Källander, C. F. R., Diderholm, H., Hagberg, H. and Pettersson, U. Int. J. Cancer 33: 5–12, 1984.PubMedCrossRefGoogle Scholar
  34. 34.
    Farthing, C, Dalgleich, A. G., Clarke, A., McClure, M., Chanas, A. and Gazzard, B. Aids Research, submitted 1987.Google Scholar
  35. 35.
    Farthing, C. F., Dalgleish, A. G., Clarke, A. L., Chanas, A., McClure, M. and Gazzard, B. G. Int. Conf. on Acquired Immunodeficiency Syndrome (AIDS), Paris, Abstract 87: S 14 e, 1986.Google Scholar
  36. 36.
    Bergdahl, S., Albert, J., Biberfeldt, G., Böttiger, B., Halvarsson, M., Julander, I., Lernestedt, J.O., Morfeldt-Mansson, L., Åsjö, B. and von Stedingk, L. V. Manuscript.Google Scholar
  37. 37.
    Gaub, J., Pedersen, C., Poulsen, A.-G., Mathiesen, L. R., Ulrich, K., Lindhardt, B. O., Faber, V., Gerstoft, J., Hofmann, B., Lernestedt, J.-O., Nielsen, J. O., Nielsen, C. M. and Platz, P. Manuscript.Google Scholar
  38. 38.
    Hartshorn, K. L., Sandström, E. G., Neumeyer, D., Paradis, T. J., Chou, T.-C, Scholey, R. L. and Hirsch, M. S. Antimicrob. Ag. Chemother. 30: 189–191, 1986a.Google Scholar
  39. 39.
    Hedin, G., Weiland, O., Ljunggren, K., Strömberg, A., Nordenfelt, E., Hansson, B.-G. and öberg, B. In: The Hepatitis Delta and its Infection (Eds. M. Rizzetto et al.), A. R. Liss Inc. In press, 1986.Google Scholar
  40. 40.
    Wyszynka, T., Jung, H., Madalinski, K., Morzycka, M. Int. J. Pediatr. Nephrol. 5: 147–153, 1984.Google Scholar
  41. 41.
    Price, J. S., France, A. J., Moaven, L. D. and Welsby, P. D. Lancet II: 1273, 1986.Google Scholar
  42. 42.
    Sherker, A. H., Hirota, K., Omata, M. and Okuda, K. Gastroenterol. 91: 818–824, 1986.Google Scholar
  43. 43.
    Blohmé, I., Ahlmén, J., Jeansson, S., Ranch, T. and Brynger, H. Transplantation Proceedings XVI. 1672–1674, 1984.Google Scholar

Copyright information

© Martinus Nijhoff Publishing 1988

Authors and Affiliations

  • B. Öberg
    • 1
  • S. Behrnetz
    • 2
  • B. Eriksson
    • 2
  • H. Jozwiak
    • 2
  • A. Larsson
    • 2
  • J. O. Lernestedt
    • 2
  • V. Lindsö Aberg
    • 2
  1. 1.Department of Antiviral ChemotherapyASTRA ALAB ABSödertäljeSweden
  2. 2.Department of Clinical ResearchASTRA ALAB ABSödertäljeSweden

Personalised recommendations